Alberto Papi

Prof. Dr. Alberto Papi

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in The Lancet
Verified
Journal Article
Closed access
APAlberto Papi
Alberto Papi
CBChristopher Brightling
Christopher Brightling
SPSøren E Pedersen
Søren E Pedersen
HRHelen K Reddel
Helen K Reddel

7 March 2019 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
DSDave Singh
Dave Singh
AAAlvar Agusti
Alvar Agusti
AAAntonio Anzueto
Antonio Anzueto
PBPeter Barnes
Peter Barnes
JBJean Bourbeau
Jean Bourbeau
CVClaus Vogelmeier
Claus Vogelmeier
Precision medicine is a patient-specific approach that integrates all relevant clinical, genetic and biological information in order to optimise the therapeutic benefit relative to the possibility of side-effects for each individual. Recent clinical trials have shown that higher blood eosinophil counts are associated with a greater efficacy of inhaled corticosteroids (ICSs) in chronic obstructive pulmonary disease (COPD) patients. Blood eosinophil counts are a biomarker with potential to be used in clinical practice, to help target ICS treatment with more precision in COPD patients with a history of exacerbations despite appropriate bronchodilator treatment.The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 pharmacological treatment algorithms, based on the ABCD assessment, can be applied relatively easily to treatment-naive individuals at initial presentation. However, their use is more problematic during follow-up in patients who are already on maintenance treatment. There is a need for a different system to guide COPD pharmacological management during follow-up.Recent large randomised controlled trials have provided important new information concerning the therapeutic effects of ICSs and long-acting bronchodilators on exacerbations. The new evidence regarding blood eosinophils and inhaled treatments, and the need to distinguish between initial and follow-up pharmacological management, led to changes in the GOLD pharmacological treatment recommendations. This article explains the evidence and rationale for the GOLD 2019 pharmacological treatment recommendations.

1 March 2023 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
AAAlvar Agustí
Alvar Agustí
BCBartolome R. Celli
Bartolome R. Celli
GCGerard J. Criner
Gerard J. Criner
DHDavid Halpin
David Halpin
AAAntonio Anzueto
Antonio Anzueto
CVClaus F. Vogelmeier
Claus F. Vogelmeier
Executive summary of the Global Strategy for Prevention, Diagnosis and Management of COPD 2023: the latest evidence-based strategy document from the Global Initiative for Chronic Obstructive Lung Disease (GOLD ) https://bit.ly/3KCaTGe

3 April 2013 in Physical Review Letters
Verified
Journal Article
Open access
PDF file
MAM. Aguilar
M. Aguilar
GAG. Alberti
G. Alberti
BAB. Alpat
B. Alpat
AAA. Alvino
A. Alvino
GAG. Ambrosi
G. Ambrosi
ACAMS Collaboration
AMS Collaboration
A precision measurement by the Alpha Magnetic Spectrometer on the International Space Station of the positron fraction in primary cosmic rays in the energy range from 0.5 to 350 GeV based on 6.8×106 positron and electron events is presented. The very accurate data show that the positron fraction is steadily increasing from 10 to ∼250  GeV, but, from 20 to 250 GeV, the slope decreases by an order of magnitude. The positron fraction spectrum shows no fine structure, and the positron to electron ratio shows no observable anisotropy. Together, these features show the existence of new physical phenomena.

15 May 2006 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
APAlberto Papi
Alberto Papi
CBCinzia Maria Bellettato
Cinzia Maria Bellettato
FBFausto Braccioni
Fausto Braccioni
MRMicaela Romagnoli
Micaela Romagnoli
PCPaolo Casolari
Paolo Casolari
SJSebastian L Johnston
Sebastian L Johnston
Rationale: Severe exacerbations of chronic obstructive pulmonary disease (COPD) are major causes of health care costs mostly related to hospitalization. The role of infections in COPD exacerbations is controversial. Objectives: We investigated whether COPD exacerbations requiring hospitalization are associated with viral and/or bacterial infection and evaluated relationships among infection, exacerbation severity, assessed by reduction of FEV1, and specific patterns of airway inflammation. Methods: We examined 64 patients with COPD when hospitalized for exacerbations, and when in stable convalescence. We measured lung function, blood gases, and exhaled nitric oxide, and examined sputum for inflammation and for viral and bacterial infection. Results: Exacerbations were associated with impaired lung function (p < 0.01) and increased sputum neutrophilia (p < 0.001). Viral and/or bacterial infection was detected in 78% of exacerbations: viruses in 48.4% (6.2% when stable, p < 0.001) and bacteria in 54.7% (37.5% when stable, p = 0.08). Patients with infectious exacerbations (29.7% bacterial, 23.4% viral, 25% viral/bacterial coinfection) had longer hospitalizations (p < 0.02) and greater impairment of several measures of lung function (all p < 0.05) than those with noninfectious exacerbations. Patients with exacerbations with coinfection had more marked lung function impairment (p < 0.02) and longer hospitalizations (p = 0.001). Sputum neutrophils were increased in all exacerbations (p < 0.001) and were related to their severity (p < 0.001), independently of the association with viral or bacterial infections; sputum eosinophils were increased during (p < 0.001) virus-associated exacerbations. Conclusions: Respiratory infections are associated with the majority of COPD exacerbations and their severity, especially those with viral/bacterial coinfection. Airway neutrophilia is related to exacerbation severity regardless of viral and/or bacterial infections. Eosinophilia is a good predictor of viral exacerbations.

13 August 2006 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MCMarco Contoli
Marco Contoli
SMSimon D Message
Simon D Message
VLVasile Laza-Stanca
Vasile Laza-Stanca
MEMichael R Edwards
Michael R Edwards
PWPeter Wark
Peter Wark
SJSebastian L Johnston
Sebastian L Johnston